US › Healthcare

Lexeo Therapeutics, Inc. Common Stock (LXEO)

US · Healthcare · Biotechnology

$4.18+0.48%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-25.9M

EPS

$-0.30

EPS estimate

$-0.30

EPS came in at -0.30 against a street estimate of -0.30 — a beat of 0.0%.

Key statistics

Market cap

$348.7M

Forward P/E

7.7

P/B

1.48

Book value

$2.99

EPS (TTM)

$-0.88

52-week high

$10.99

52-week low

$3.99

50-day MA

$4.72

200-day MA

$6.30

Beta

1.50

Analyst view

Analysts rate Lexeo Therapeutics, Inc. Common Stock a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $20.30.

Shareholding

Insiders

0.64%

Institutions

114.41%

Largest institutional holders

Fund	Stake
Affinity Asset Advisors, LLC	7.08%
BlackRock Inc	6.23%
RA Capital Management, LLC	6.09%
HHG PLC	6.07%
Vestal Point Capital LP	5.45%
Frazier Life Sciences Management, L.P.	5.39%
Paradigm Biocapital Advisors LP	5.09%
Citadel Advisors Llc	4.75%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexeo Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.